These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21898091)

  • 21. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.
    Chaise C; Buchan SL; Rice J; Marquet J; Rouard H; Kuentz M; Vittes GE; Molinier-Frenkel V; Farcet JP; Stauss HJ; Delfau-Larue MH; Stevenson FK
    Blood; 2008 Oct; 112(7):2956-64. PubMed ID: 18502835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. WT1 peptide cancer vaccine for patients with hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Elisseeva OA; Nakajima H; Fujiki F; Kawakami M; Shirakata T; Nishida S; Hosen N; Oji Y; Kawase I; Sugiyama H
    ScientificWorldJournal; 2007 May; 7():649-65. PubMed ID: 17619750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
    Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
    Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides.
    Brayer J; Lancet JE; Powers J; List A; Balducci L; Komrokji R; Pinilla-Ibarz J
    Am J Hematol; 2015 Jul; 90(7):602-7. PubMed ID: 25802083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CDR3α drives selection of the immunodominant Epstein Barr virus (EBV) BRLF1-specific CD8 T cell receptor repertoire in primary infection.
    Kamga L; Gil A; Song I; Brody R; Ghersi D; Aslan N; Stern LJ; Selin LK; Luzuriaga K
    PLoS Pathog; 2019 Nov; 15(11):e1008122. PubMed ID: 31765434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biased usage of BV gene families of T-cell receptors of WT1 (Wilms' tumor gene)-specific CD8+ T cells in patients with myeloid malignancies.
    Tanaka-Harada Y; Kawakami M; Oka Y; Tsuboi A; Katagiri T; Elisseeva OA; Nishida S; Shirakata T; Hosen N; Fujiki F; Murao A; Nakajima H; Oji Y; Kanda Y; Kawase I; Sugiyama H
    Cancer Sci; 2010 Mar; 101(3):594-600. PubMed ID: 20132220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
    Sensi M; Traversari C; Radrizzani M; Salvi S; Maccalli C; Mortarini R; Rivoltini L; Farina C; Nicolini G; Wölfel T
    Proc Natl Acad Sci U S A; 1995 Jun; 92(12):5674-8. PubMed ID: 7777568
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report.
    Sonntag K; Hashimoto H; Eyrich M; Menzel M; Schubach M; Döcker D; Battke F; Courage C; Lambertz H; Handgretinger R; Biskup S; Schilbach K
    J Transl Med; 2018 Feb; 16(1):23. PubMed ID: 29409514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Establishment of a stable T lymphoma cell line transduced with HLA-A*24:02-restricted WT1-specific TCR genes and its application to antigen-specific immunomonitoring.
    Watanabe K; Toji S; Ohtake J; Nakano K; Satoh T; Kitamura H; Nishimura T
    Biomed Res; 2013 Feb; 34(1):41-50. PubMed ID: 23428979
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of B cell-bound HLA-A2 class I monomers to generate high-avidity, allo-restricted CTLs against the leukemia-associated protein Wilms tumor antigen.
    Savage P; Gao L; Vento K; Cowburn P; Man S; Steven N; Ogg G; McMichael A; Epenetos A; Goulmy E; Stauss HJ
    Blood; 2004 Jun; 103(12):4613-5. PubMed ID: 14988155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
    Asemissen AM; Keilholz U; Tenzer S; Müller M; Walter S; Stevanovic S; Schild H; Letsch A; Thiel E; Rammensee HG; Scheibenbogen C
    Clin Cancer Res; 2006 Dec; 12(24):7476-82. PubMed ID: 17189421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8
    Xiang SD; Wilson KL; Goubier A; Heyerick A; Plebanski M
    Front Immunol; 2018; 9():2968. PubMed ID: 30631324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-vivo dominant immune responses in aplastic anaemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing.
    Risitano AM; Maciejewski JP; Green S; Plasilova M; Zeng W; Young NS
    Lancet; 2004 Jul 24-30; 364(9431):355-64. PubMed ID: 15276395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decade-long WT1-specific CTLs induced by WT1 peptide vaccination.
    Suwabe T; Shibasaki Y; Tamura S; Katagiri T; Fuse K; Ida-Kurasaki T; Ushiki T; Sone H; Narita M; Masuko M
    Int J Hematol; 2024 Apr; 119(4):399-406. PubMed ID: 38427208
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Identification of a public CDR3 motif and a biased utilization of T-cell receptor V beta and J beta chains in HLA-A2/Melan-A-specific T-cell clonotypes of melanoma patients.
    Serana F; Sottini A; Caimi L; Palermo B; Natali PG; Nisticò P; Imberti L
    J Transl Med; 2009 Mar; 7():21. PubMed ID: 19317896
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting of the WT1
    Dagvadorj N; Deuretzbacher A; Weisenberger D; Baumeister E; Trebing J; Lang I; Köchel C; Kapp M; Kapp K; Beilhack A; Hünig T; Einsele H; Wajant H; Grigoleit GU
    Cancer Immunol Immunother; 2017 Mar; 66(3):319-332. PubMed ID: 27896368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.
    Casalegno-Garduño R; Schmitt A; Spitschak A; Greiner J; Wang L; Hilgendorf I; Hirt C; Ho AD; Freund M; Schmitt M
    Int J Cancer; 2016 Apr; 138(7):1792-801. PubMed ID: 26519872
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Detection of Wilms' tumor antigen--specific CTL in tumor-draining lymph nodes of patients with early breast cancer.
    Gillmore R; Xue SA; Holler A; Kaeda J; Hadjiminas D; Healy V; Dina R; Parry SC; Bellantuono I; Ghani Y; Coombes RC; Waxman J; Stauss HJ
    Clin Cancer Res; 2006 Jan; 12(1):34-42. PubMed ID: 16397021
    [TBL] [Abstract][Full Text] [Related]  

  • 40. WT1 peptide vaccine for the treatment of cancer.
    Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
    Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.